全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Implementation of QbD Approach to the Analytical Method Development and Validation for the Estimation of Propafenone Hydrochloride in Tablet Dosage Form

DOI: 10.1155/2013/676501

Full-Text   Cite this paper   Add to My Lib

Abstract:

Chromatographic and spectrophotometric methods were developed according to Quality by Design (QbD) approach as per ICH Q8(R2) guidelines for estimation of propafenone hydrochloride in tablet dosage form. QbD approach was carried out by varying various parameters and these variable parameters were designed into Ishikawa diagram. The critical parameters were determined by using principal component analysis as well as by observation. Estimated critical parameters in HPTLC method include solvent methanol, mode of detection absorbance, precoated aluminium backed TLC plate (10?cm 10?cm), wavelength: 250?nm, saturation time: 20?min, band length: 8?mm, solvent front: 70?mm, volume of mobile phase: 5?mL, type of chamber: 10?cm 10?cm, scanning time: 10?min, and mobile phase methanol?:?ethyl acetate?:?triethylamine (1.5?:?3.5?:?0.4?v/v/v). Estimated critical parameters in zero order spectrophotometric method were solvent methanol, sample preparation tablet, wavelength: 247.4?nm, slit width: 1.0, scan speed medium, and sampling interval: 0.2, and for first order derivative spectrophotometric method it was scaling factor: 5 and delta lambda 4. The above methods were validated according to ICH Q2(R1) guidelines. Proposed methods can be used for routine analysis of propafenone hydrochloride in tablet dosage form as they were found to be robust and specific. 1. Introduction Quality by Design approach suggests looking into the quality of analytical process during the development stage itself. It says that quality should be built into the process design rather than testing into final results of analytical process [1]. QbD is defined as “a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding based on sound science and quality risk management” [2]. In alignment with the approach proposed in the draft FDA guidance for process validation, a three-stage approach [3] can be applied to method validation. Stage 1. Method Design. Define method requirements and conditions and identify critical controls. Stage 2. Method Qualification. Confirm that the method is capable of meeting its design intent. Stage 3. Continued Method Verification. Gain ongoing assurance to ensure that the method remains in a state of control during routine use. A critical function of Stage 1 is the design of an Analytical Target Profile (ATP) for the method. To design the ATP, it is necessary to determine the characteristics that will be indicators of method performance for its intended use. These are selected from the performance

References

[1]  ICH Topic Q8 (R2), “ICH harmonised tripartite guideline,” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '09), Pharmaceutical Development, 2009.
[2]  A. B. Godfrey and R. S. Kenett, “Joseph M. Juran, a perspective on past contributions and future impact,” Quality and Reliability Engineering International, vol. 23, no. 6, pp. 653–663, 2007.
[3]  P. Nethercote, P. Borman, T. Bennett, et al., QbD for Better Method Validation & Transfer, Pharmaceutical Manufacturing, 2010.
[4]  ICH Topic Q2 (R1), “ICH harmonised tripartite guideline,” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '94), Validation of Analytical Procedures, 1994.
[5]  ICH Topic Q9, “ICH harmonised tripartite guideline,” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '94), Quality Risk Management, 2005.
[6]  P. Borman, P. Nethercote, M. Chatfield, et al., The Application of Quality by Design to Analytical Methods, PharmTech, 2007.
[7]  L. X. Yu, “Pharmaceutical quality by design: product and process development, understanding, and control,” Pharmaceutical Research, vol. 25, no. 4, pp. 781–791, 2008.
[8]  M. Pohl, M. Schweitzer, G. Hansen et al., “Implications and opportunities of applying the principles of QbD to analytical measurements,” Pharmaceutical Technology Europe, vol. 22, no. 2, pp. 29–36, 2010.
[9]  The United States Pharmacopoeia 27, the National Formulary 22, Asian Edition, United States Pharmacopoeial Convection, 2004.
[10]  C. M. de Gaitani, V. L. Lanchote, and P. S. Bonato, “Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions,” Journal of Chromatography B, vol. 708, no. 1-2, pp. 177–183, 1998.
[11]  Y. Wu, M. Ma, and S. Zeng, “Enantioselective assay of S(+)- and R(-)-propafenone in human urine by using RP-HPLC with pre-column chiral derivatization,” Journals of Zhejiang University-Science A, vol. 5, no. 2, pp. 226–229, 2004.
[12]  D. Zhong and X. Chen, “Enantioselective determination of propafenone and its metabolites in human plasma by liquid chromatography-mass spectrometry,” Journal of Chromatography B, vol. 721, no. 1, pp. 67–75, 1999.
[13]  L. R. P. de Abreu, V. L. Lanchote, C. Bertucci, E. J. Cesarino, and P. S. Bonato, “Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase,” Journal of Pharmaceutical and Biomedical Analysis, vol. 20, no. 1-2, pp. 209–216, 1999.
[14]  U. Hofmann, M. Pecia, G. Heinkele, K. Dilger, H. K. Kroemer, and M. Eichelbaum, “Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography-electrospray ionization mass spectrometry,” Journal of Chromatography B, vol. 748, no. 1, pp. 113–123, 2000.
[15]  M. Schweitzer, M. Pohl, M. Hanna-Brown, et al., “Implications and opportunities of applying QbD principles to analytical measurements,” Pharmaceutical Technology, vol. 34, no. 2, pp. 52–59, 2010.
[16]  R. M. Bianchini, P. M. Castellano, and T. S. Kaufman, “Development and validation of an HPLC method for the determination of process-related impurities in pridinol mesylate, employing experimental designs,” Analytica Chimica Acta, vol. 654, no. 2, pp. 141–147, 2009.
[17]  K. Monks, I. Molnar, H. J. Rieger, B. Bogati, and E. Szabo, “Quality by design: multidimensional exploration of the design space in high performance liquid chromatography method development for better robustness before validation,” Journal of Chromatography A, vol. 1232, pp. 218–230, 2012.
[18]  G. Srinubabu, C. A. I. Raju, N. Sarath, P. K. Kumar, and J. V. L. N. S. Rao, “Development and validation of a HPLC method for the determination of voriconazole in pharmaceutical formulation using an experimental design,” Talanta, vol. 71, no. 3, pp. 1424–1429, 2007.
[19]  S. M. Khamanga and R. B. Walker, “The use of experimental design in the development of an HPLC-ECD method for the analysis of captopril,” Talanta, vol. 83, no. 3, pp. 1037–1049, 2011.
[20]  E. M. Sheldon and J. B. Downar, “Development and validation of a single robust HPLC method for the characterization of a pharmaceutical starting material and impurities from three suppliers using three separate synthetic routes,” Journal of Pharmaceutical and Biomedical Analysis, vol. 23, no. 2-3, pp. 561–572, 2000.
[21]  P. F. Gavin and B. A. Olsen, “A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603),” Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 3, pp. 431–441, 2008.
[22]  B. Dejaegher and Y. vander Heyden, “Experimental designs and their recent advances in set-up, data interpretation, and analytical applications,” Journal of Pharmaceutical and Biomedical Analysis, vol. 56, no. 2, pp. 141–158, 2011.
[23]  D. Awotwe-Otooa, C. Agarabia, P. J. Faustinoa et al., “Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate,” Journal of Pharmaceutical and Biomedical Analysis, vol. 62, pp. 61–67, 2012.
[24]  B. Vasselle, G. Gousset, and J. P. Bounine, “Development and validation of a high-performance liquid chromatographic stability-indicating method for the analysis of Synercid in quality control, stability and compatibility studies,” Journal of Pharmaceutical and Biomedical Analysis, vol. 19, no. 5, pp. 641–657, 1999.

Full-Text

Contact Us

[email protected]

QQ:3279437679

WhatsApp +8615387084133